



**C Kollmannsberger**

**Contact**

C Kollmannsberger

## Publications (5)

Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Lorient Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. *Ann Oncol* 2019; 23:59-64.

Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J, Lorch A, Looijenga L, Laguna M, Krege S, Kollmannsberger C, Kliesch S, Huddart R, Oechsle K, Oldenburg J, Oosterhuis J, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A, Cohn-Cedermark G, Classen J, Clarke N, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J, Giwercman A, Gillessen S, Gietema J, Germá Lluch J, Fossa S, Fléchon A, Fizazi K, Fenner M, Dieckmann K, De Wit R, Beyer J. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol* 2012; 24:878-88.

Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. *Invest New Drugs* 2012; 31:661-8.

Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Lorient Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-<sup>18</sup>F-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. *Ann Oncol* 2011; 23:59-64.

Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). *Ann Oncol* 2006; 17:1007-13.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)